A BBC News investigation has examined how consumer demand for Eli Lilly’s investigational triple-hormone-receptor agonist retatrutide is fueling an industry of counterfeit and unapproved versions sold through unregulated channels.
The report comes as retatrutide remains in clinical development and has not received FDA approval. Eli Lilly has stated it plans to submit its FDA application in the first quarter of 2027, meaning any potential US launch would not come before late 2027 — and that timeline could shift.
The investigation highlights the risks facing consumers who seek out purported retatrutide during this extended pre-approval period, when no approved version of the drug exists on the market.
What happened
The BBC News investigation detailed how demand for retatrutide — an investigational drug that has not been approved by any major regulator — is being met by sellers operating outside approved pharmaceutical supply chains. The report described examples of counterfeit and unapproved versions reaching consumers through unregulated channels, with cases reported in the UK and beyond.
Retatrutide is currently being developed by Eli Lilly as a triple-hormone-receptor agonist. Because the drug has not completed the regulatory approval process, any product sold as retatrutide outside of clinical trials is not an approved pharmaceutical.
Why it matters
Mainstream media attention on gray-market peptide sales could amplify consumer awareness of the risks associated with unregulated sources. The BBC report may also contribute to increased adverse event reporting and add pressure on regulators and online platforms to act.
The timeline for Eli Lilly’s FDA application — with a planned filing in Q1 2027 and a potential launch no earlier than late 2027 — establishes a clear window during which no approved retatrutide product will be available. During that period, enforcement actions against unapproved versions are expected to remain active.
The investigation also underscores broader concerns about the gray-market peptide supply chain, which has grown around investigational drugs that generate significant consumer interest before they reach the market.
What to watch next
- Whether the BBC investigation prompts additional regulatory enforcement against sellers of unapproved retatrutide
- Eli Lilly’s progress toward its planned Q1 2027 FDA filing and any updates to the approval timeline
- Whether mainstream coverage leads to increased adverse event reports tied to counterfeit or unapproved retatrutide
- How online platforms and telehealth providers respond to heightened scrutiny of gray-market peptide sales
Sources
Industry information only. Not medical or legal advice.
